ESC 2026: Landmark Event for ATTR-CM w/ Pot’l CARDIO-TTRansform Data

Research evidence excerpt

ESC 2026: Landmark Event for ATTR-CM w/ Pot’l CARDIO-TTRansform Data

Alnylam Pharmaceuticals, Inc (ALNY)

Equity Research

July 2, 2026

Here's our 'first glance' of titles at ESC 2026 relevant to ATTR-CM / ALNY / Amvuttra / nucresiran:

Date Session Time Abstract title

28-Aug HOT LINE 1 11:00 CARDIO-TTRansform: efficacy and safety of eplontersen in patients with transthyretin amyloid cardiomyopathy

Ageing-related cardiovascular phenotypes: from frailty to Age-dependent sex differences and tafamidis treatment-associated outcomes in transthyretin wild-type cardiac

28-Aug multimorbidity care 11:15-12:00 amyloidosis: a nationwide multicenter study

Multimodality cardiac computed tomography and

cardiovascular magnetic resonance in pericardial and Differential effects of Tafamidis on cardiac remodelling in transthyretin amyloid cardiomyopathy: evidence from

28-Aug myocardial disease 13:15-14:00 contemporary imaging data

28-Aug Diagnosis and risk stratification in cardiac amyloidosis 15:15-16:00 Risk prediction in ATTR-CM patients under tafamidis treatment: results from the multicentre SWISS-CARE registry

Understanding thick hearts: diagnostic pathways and

28-Aug therapeutic mechanisms 15:40 Clinical evidence for vutrisiran in transthyretin cardiomyopathy

Cardiac magnetic resonance of amyloidosis and myocardial Long-term improvement in myocardial structure and function in patients with transthyretin amyloid cardiomyopathy

28-Aug remodelling 16:15-17:00 (ATTR-CM) treated with acoramidis compared with a natural history cohort

Cardiac magnetic resonance of amyloidosis and myocardial Longitudinal changes in amyloid burden as measured by extracellular volume (ECV) on cardiac MRI for patients with

28-Aug remodelling 16:15-17:00 transthyretin amyloidosis with cardiomyopathy (ATTR-CM)